MARKET

TBIO

TBIO

TRANSLATE BIO, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.07
+0.03
+0.37%
Closed 16:00 01/21 EST
OPEN
8.03
PREV CLOSE
8.04
HIGH
8.25
LOW
7.93
VOLUME
207.38K
TURNOVER
--
52 WEEK HIGH
14.34
52 WEEK LOW
4.810
MARKET CAP
348.04M
P/E (TTM)
-4.3626
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of TBIO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

TBIO News

  • Translate Bio, Inc. (TBIO): Are Hedge Funds Right About This Stock?
  • Insider Monkey.12/14/2019 22:18
  • Translate Bio Names Paul Burgess COO
  • Benzinga.12/12/2019 21:26
  • Translate Bio Announces Executive Leadership Appointments
  • GlobeNewswire.12/12/2019 21:15
  • Seth Klarman Pares Paratek Pharmaceuticals Stake
  • GuruFocus.com.12/10/2019 17:22

More

Industry

Biotechnology & Medical Research
-0.61%
Pharmaceuticals & Medical Research
-0.38%

Hot Stocks

Name
Price
%Change

About TBIO

Translate Bio, Inc. is a messenger RNA, or mRNA, therapeutics company. The Company is developing medicines to treat diseases caused by protein or gene dysfunction. The Company is using its proprietary mRNA therapeutic platform, or MRT platform, and it create mRNA that encodes functional proteins. The mRNA is delivered to the target cell where the cell’s own machinery recognizes it and translates it, restoring or augmenting protein function to treat or prevent disease. The MRT product candidate for the lung, MRT5005, is designed to address the underlying cause of CF by delivering mRNA encoding fully functional CFTR protein to the lung epithelial cells through nebulization.
More

Webull offers Translate Bio Inc (TBIO) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.